1. Home
  2. MXCT
  3. Earnings

AI Earnings Predictions for MaxCyte Inc. (MXCT)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

BUY

1-Day Prediction

+6.07%

$1.25

99% positive prob.

5-Day Prediction

+11.91%

$1.32

99% positive prob.

20-Day Prediction

+8.12%

$1.28

94% positive prob.

Price at prediction: $1.18 Confidence: 98.9% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 BUY +6.07% +11.91% +8.12% 98.9% Pending
Q3 2026 BUY +5.83% +10.59% +9.31% 87.2% Pending
Q2 2026 SELL -8.24% -10.36% -9.07% 100.0% Pending
Q1 2026 BUY +3.60% +9.63% +8.22% 99.7% +26.49%
Q4 2025 SELL -8.78% -10.78% -8.62% 99.9% -11.03%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 10, 2026 · 87% conf.

AI Prediction BUY

1D

+5.83%

$1.35

Act: +4.84%

5D

+10.59%

$1.42

20D

+9.31%

$1.40

Price: $1.28 Prob +5D: 94% AUC: 1.000
0001104659-26-124829

EX-99.1

3 tm2629420d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time

Third Quarter and Recent Business Highlights:

·Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related revenue

·Raises Full Year 2026 Total Revenue Guidance to at least $34.5 million, reflecting a projected return to full-year revenue growth

·In July, MaxCyte announced a strategic, multi-platform technology license partnership with Genentech

·MaxCyte today announced the proposed acquisition of Akron Bio, a leading supplier of GMP-grade reagents and ancillary materials, expanding its offering across cell therapy manufacturing and nearly doubling revenue

ROCKVILLE,

MD, November 10, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2026 financial results and raised its 2026 total revenue guidance.

"Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value,” said Maher Masoud, President and CEO of MaxCyte. “MaxCyte’s third quarter results reflect the progress that we have made throughout 2026, with approximately 15% year-over-year core revenue growth expected in the second half of this year, exceeding the growth expectations we established at the beginning of 2026. Looking ahead, our SPL partners are at the forefront of cell therapy program development, with more late-stage programs than ever before, including two pivotal trials that could result in approvals as early as next year. Our enterprise pharma partnership is off to a strong start and represents an exciting opportunity to support its advancing cell therapy pipeline. Together, with building adoption in early research, we now have a broad set of solutions at every stage, from discovery through commercialization. We believe we have strong momentum heading into the end of the year and remain committed to executing on our priorities to drive durable long-term growth.”

Third Quarter Financial Results

·Total revenue of $10.2 million in the third quarter of 2026, an increase of 49% over the third quarter of 2025.

oCore business revenue of $8.2 million in the third quarter of 2026, an increase of 27% over the third quarter of 2025.

oStrategic Platform License (SPL) Program-related revenue was $2.0 million for the third quarter of 2026, compared to $0.4 million in the third quarter of 2025.

1

·Gross profit for the third quarter of 2026 was $8.5 million (83% gross margin), compared to $5.2 million (77% gross margin) in the third quarter of 2025.

·Non-GAAP adjusted gross margin was 80% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 81% in the third quarter of 2025.

·Operating expenses for the third quarter of 2026 were $14.5 million, compared to operating expenses of $19.4 million in the third quarter of 2025.

·Third quarter 2026 net loss was $4.8 million compared to net loss of $12.4 million for the same period in 2025.

·EBITDA,

a non-GAAP measure, was a loss of $5.1 million for the third quarter of 2026, compared to

a loss of $13.1 million for the third quarter of 2025; stock-based compensation expense was $1.0 million in the third quarter of 2026 compared to $2.0 million in the third quarter of 2025.

·Total SPL agreements was 28 as of September 30, 2026, which includes 13 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.

·Total cash, cash equivalents and investments were $132.7 million as of September 30, 2026.

Full Year 2026 Guidance

·Excluding the impact of the Akron acquisition, full year revenue is now expected to be at least $34.5 million, consisting of:

oCore revenue of approximately $28 million.

oSPL Program-related revenue of at least $6.5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $4 million from milestone payments and at least $2.5 million from commercial royalties.

·Assuming the close of the Akron acquisition, MaxCyte expects to have approximately $40.0 to $45.0 million in total cash, cash equivalents and investments as of the end of 2026, which accounts for an estimated $105.0 million paid in cash and acquisition deal expenses, along with $22.0 million drawn under the MidCap Financial credit facility financing.

·On a pro forma basis, excluding the impact of the Akron acqui

2026
Q3

Q3 2026 Earnings

8-K BUY

Oct 14, 2026 · 87% conf.

AI Prediction BUY

1D

+5.83%

$1.35

Act: +4.84%

5D

+10.59%

$1.42

20D

+9.31%

$1.40

Price: $1.28 Prob +5D: 94% AUC: 1.000
0001104659-26-115745

Transcript text not available. View on SEC.gov →

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 12, 2026 · 100% conf.

AI Prediction SELL

1D

-8.24%

$1.17

Act: +9.47%

5D

-10.36%

$1.14

20D

-9.07%

$1.15

Price: $1.27 Prob +5D: 0% AUC: 1.000
0001104659-26-094886

EX-99.1

2 mxct-20260812xex99d1.htm

EX-99.1

Exhibit 99.1

​

MaxCyte Reports Second Quarter 2026 Financial Results

·

Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue

·

Reiterates Full Year 2026 Guidance

·

Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board

·

Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July

ROCKVILLE, MD, August 12, 2026 — MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2026 financial results and reiterated its 2026 guidance.

"We are pleased with our second quarter results, which were ahead of our expectations, driven by execution on instrument placements and stability in processing assembly sales," said Maher Masoud, President and CEO of MaxCyte. "A significant development for MaxCyte was the recent signing of our first multi-platform technology license partnership with large pharma, an enterprise-level agreement with Genentech that we believe will unlock meaningful new opportunities for MaxCyte. Separately, our SPL portfolio remains a key driver of long-term value as evident by growing commercial royalty revenue and the advancement of a significant number of SPL programs through the clinic. Lastly, our goal has been to return to revenue growth while reducing our net losses. In the first half of 2026, we delivered a meaningful reduction in net loss and expect to benefit further as we continue to execute against our plan and return to revenue growth.”

Second Quarter Financial Results

·

Total revenue of $7.3 million in the second quarter of 2026, a decrease of 15% over the second quarter of 2025.

o

Core business revenue of $6.5 million in the second quarter of 2026, a decrease of 21% over the second quarter of 2025.

o

Strategic Platform License (SPL) Program-related revenue was $0.8 million for the second quarter of 2026, compared to $0.3 million in the second quarter of 2025.

·

Gross profit for the second quarter of 2026 was $5.6 million (77% gross margin), compared to $7.0 million (82% gross margin) in the second quarter of 2025.

·

Non-GAAP adjusted gross margin was 77% when excluding SPL Program-related revenue and reserves for excess and obsolete inventory, compared to non-GAAP adjusted gross margin of 83% in the second quarter of 2025.

·

Operating expenses for the second quarter of 2026 were $15.8 million, compared to operating expenses of $21.2 million in the second quarter of 2025.

·

Second quarter 2026 net loss was $8.9 million compared to net loss of $12.4 million for the same period in 2025.

​

1

·

EBITDA, a non-GAAP measure, was a loss of $9.3 million for the second quarter of 2026, compared to a loss of $13.1 million for the second quarter of 2025; stock-based compensation expense was $1.2 million in the second quarter of 2026 compared to $3.5 million in the second quarter of 2025.

·

Total SPL agreements was 29 as of June 30, 2026, which includes 12 programs currently in the clinic (defined as programs with at least a cleared IND or equivalent) and one commercial program.

·

Total cash, cash equivalents and investments were $141.9 million as of June 30, 2026.

Full Year 2026 Guidance

·

Full year revenue expected to be $30 million to $32 million consisting of:

o

Core revenue of $25 million to $27 million.

o

SPL Program-related revenue of approximately $5 million for the year; SPL Program-related revenue guidance includes both revenue of approximately $3 million from milestone payments and approximately $2 million from commercial royalties.

·

MaxCyte expects to end 2026 with at least $130.5 million in total cash, cash equivalents and investments, excluding any further capital deployed toward the share repurchase program.

The following tables provide details regarding the sources of our revenue for the periods presented.

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

​

​

​

June 30 (Unaudited)

​

​

​

​ ​ ​

2026

​ ​ ​

2025

​ ​ ​

%

(in thousands, except percentages)

​

​

​

​

​

​

​

​

Instruments

​

$

1,761

​

$

2,141

​

(18%)

PAs and Consumables

​

​

2,337

​

​

3,128

​

(25%)

Licenses

​

​

1,822

​

​

2,619

​

(30%)

Assay Service

​

​

245

​

​

51

​

380%

Other

​

​

338

​

​

259

​

31%

Total Core Revenue

​

$

6,503

​

$

8,198

​

(21%)

Milestones

​

​

4

​

​

4

​

0%

Royalties

​

​

764

​

​

305

​

150%

Total Revenue

​

$

7,271

​

$

8,507

​

(15%)

​

Webcast and Conference Call Details

MaxCyte will host a conference call today, August 12, 2026, at 4:30 p.m. Eastern Time. Investors interested in li

About MaxCyte Inc. (MXCT) Earnings

This page provides MaxCyte Inc. (MXCT) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on MXCT's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: